DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2021 Earnings Conference Call August 12, 2021 8:00 AM ET Company Participants Rick Pauls - President, CEO & Director Scott Kellen - CFO & Company Secretary Conference Call Participants Etzer Darout - Guggenheim Securities Alex Nowak - Craig-Hallum Capital Thomas Flaten - Lake Street Capital Francois Brisebois - Oppenheimer Operator Good morning, ladies and gentlemen. And welcome to the DiaMedica Therapeutics Second Quarter 2021 Conference Call. An audio recording ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from __ ...

Financial Data and Key Metrics Changes - The net loss for Q1 2021 was $3.6 million or $0.19 per share, compared to a net loss of $2.4 million or $0.19 per share for the same period in the prior year [18] - Research and development expenses increased to $2.4 million from $1.4 million year-over-year, attributed to costs for the REDUX Phase 2 CKD study and increased staffing [19] - General and administrative expenses rose slightly to $1.2 million from $1.1 million, primarily due to higher insurance premiums and personnel costs [20] - Cash, cash equivalents, and marketable securities at the end of Q1 2021 were $23.4 million, down from $27.5 million at the end of 2020 [21][22] Business Line Data and Key Metrics Changes - The Acute Ischemic Stroke program is advancing with a Phase 2/3 study of DM199, with the IND submitted on April 16, 2021 [8][9] - Enrollment in the REDUX study reached 70 participants, with full enrollment of the diabetic kidney disease cohort and 70% completion in the IgA Nephropathy cohort [15][16] Market Data and Key Metrics Changes - The company is preparing for discussions with the FDA regarding stroke recurrence as a clinically significant endpoint, following positive results from the ReMEDy Phase 2 study [11][12] Company Strategy and Development Direction - The company plans to submit an application for fast-track designation for DM199 as part of the study initiation [13] - The strategy includes engaging a contract research organization to identify and qualify clinical sites for the upcoming studies [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the timelines for the Phase 2/3 study and does not anticipate significant issues with the IND submission [10][25] - The company expects to report preliminary top-line data from the diabetic kidney disease cohorts during the current quarter [15][28] Other Important Information - The company has sufficient drug supply for the study, with a shelf-life extending two years [49] - The current capital position is expected to fund operations through mid-2022, allowing completion of the REDUX study and initiation of the Phase 2/3 study [22] Q&A Session Summary Question: Status of fast-track designation submission - Management confirmed that the fast-track designation has not yet been submitted but plans to do so after receiving approval to proceed with the study [23][24] Question: Insights on kidney readout data - Management indicated that they would like to see a decrease in UACR proteinuria while maintaining or increasing eGFR [26][27] Question: Patient disposition in DKD trial - Management stated they prefer to wait for complete data before analyzing individual patient outcomes [30] Question: Implications of DKD data for IgA Nephropathy - Management discussed the potential for DM199 to improve kidney function across different causes of kidney disease, with a focus on differences among cohorts [39][40] Question: Timing for FDA approach regarding stroke recurrence - Management is exploring multiple pathways for stroke recurrence, including potential sub-studies or co-primary endpoints [35][36] Question: Activation of study sites - Management confirmed that they are in the process of identifying and activating clinical study sites, aiming for up to 75 sites [46] Question: Initial data readout expectations - Management anticipates interim results in 2022, with the study completion expected in 2023 [51]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from _ ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2020 Results Earnings Conference Call March 11, 2021 8:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Etzer Darout - Guggenheim Elemer Piros - ROTH Capital Partners Thomas Flaten - Lake Street Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Fourth Quarter 2020 Conference Call. An audio re ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2020 Earnings Conference Call November 5, 2020 8:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Thomas Flaten - Lake Street Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Third Quarter 2020 Conference Call. An audio recording of the webcast will be available shortly after t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission File Number: 001-36291 ____________________ DIAMEDICA THERAPEUTICS INC. ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2020 Earnings Conference Call August 12, 2020 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer Scott Kellen - Chief Financial Officer Harry Alcorn - Chief Medical Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Thomas Flaten - Lake Street Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2020 Financial Results Conference Call. An au ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ Title of each class Trading Symbol Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2020 Results Earnings Conference Call May 14, 2020 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer Scott Kellen - Chief Financial Officer Harry Alcorn - Chief Medical Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Thomas Flaten - Lake Street Capital Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Conference Call to discuss the topline results from DiaMedica's ...